Article PDF
References
O’Bryant SE, Mielke MM, Rissman RA, et al. Blood-based biomarkers in Alzheimer disease: Current state of the science and a novel collaborative paradigm for advancing from discovery to clinic. Alzheimers. Dement. 2017;13:45–58.
Food and Drug Administration (US); Bethesda (MD): National Institutes of Health (US) 2016.
Cummings J, Fox N, Vellas B, et al. Biomarker and Clinical Trial Design Support for Disease-Modifying Therapies: Report of a Survey of the EU/US: Alzheimer’s Disease Task Force. J. Prev. Alzheimer’s Dis. 2018;5:103–109.
Hampel H, Vergallo A, Aguilar LF, et al. Precision pharmacology for Alzheimer’s disease. Pharmacol. Res. 2018;130:331–365. doi: 10.1016/j. phrs.2018.02.014.
Hampel H, Frank R, Broich K, et al. Biomarkers for Alzheimer’s disease:academic, industry and regulatory perspectives. Nat. Rev. Drug Discov. 2010;9:560–574.
Vellas B, Carrillo MC, Sampaio C, et al. Designing drug trials for Alzheimer’s disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force. Alzheimers. Dement. United States; 2013. p. 438–444.
Drilon A, Laetsch TW, Kummar S, et al. Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. N. Engl. J. Med. 2018;378:731–739.
Hampel H, Kötter HU, Padberg F, et al. Oligoclonal bands and blood—cerebrospinal-fluid barrier dysfunction in a subset of patients with Alzheimer disease: comparison with vascular dementia, major depression, and multiple sclerosis. Alzheimer Dis. Assoc. Disord. 1999;13:9–19.
Hampel H, Kötter HU, Moller HJ. Blood-cerebrospinal fluid barrier dysfunction for high molecular weight proteins in Alzheimer disease and major depression: indication for disease subsets. Alzheimer Dis. Assoc. Disord. 1997;11:78–87.
Hampel H, Muller-Spahn F, Berger C, et al. Evidence of blood-cerebrospinal fluid-barrier impairment in a subgroup of patients with dementia of the Alzheimer type and major depression: a possible indicator for immunoactivation. Dementia. 1995;6:348–354.
Hampel H, Toschi N, Babiloni C, et al. Revolution of Alzheimer Precision Neurology. Passageway of Systems Biology and Neurophysiology. J. Alzheimers. Dis. 2018. doi: 10.3233/JAD-179932.
Hampel H, O’Bryant SE, Castrillo JI, et al. PRECISION MEDICINE-The Golden Gate for Detection, Treatment and Prevention of Alzheimer’s Disease. J. Prev. Alzheimer’s Dis. 2016;3:243–259.
Hampel H, O’Bryant SE, Durrleman S, et al. A Precision Medicine Initiative for Alzheimer’s disease: the road ahead to biomarker-guided integrative disease modeling. Climacteric. 2017;20:107–118.
Karran E, Hardy J. A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease. Ann. Neurol. 2014;76:185–205.
Aisen PS, Vellas B, Hampel H. Moving towards early clinical trials for amyloid-targeted therapy in Alzheimer’s disease. Nat. Rev. Drug Discov. England; 2013. p. 324.
Author information
Authors and Affiliations
Consortia
Corresponding author
Additional information
Speaker and coordinator of the – Sorbonne University Clinical Research Group (GRC n°21), “Alzheimer Precision Medicine (APM)”, Établissements Publics à caractère Scientifique et Technologique (E.P.S.T.), Alzheimer Precision Medicine Initiative (APMI) & Cholinergic System Working Group (CSWG)
Rights and permissions
About this article
Cite this article
Hampel, H., Vergallo, A., Bonuccelli, U. et al. Turning Point towards Blood Biomarker-Guided Targeted Therapy for Precision Medicine in Alzheimer’s Disease. J Prev Alzheimers Dis 5, 160–164 (2018). https://doi.org/10.14283/jpad.2018.25
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.14283/jpad.2018.25